血清HMGB1水平与慢性阻塞性肺疾病关系
|
摘要
目的探讨慢性阻塞性肺疾病患者血清高迁移率族蛋白B1(high mobility group protein B1,HMGB1)水平与慢性阻塞性肺疾病的相关性。方法选取我院2015年1月~2016年5月收治的慢性阻塞性肺疾病(chronic ob structive pulmonary disease,COPD)患者共计73例,为COPD组。另选取73例健康研究对象为对照组。通过用力呼气量占用力肺活量比值(FEV_1/FVC%)、用力呼气量(FEV_1)占预计值%评价两组研究对象的肺功能;采用酶联免疫吸附试验(ELISA)方法检测两组研究对象血清HMGB1水平并进行比较,分析血清HMGB1水平与肺功能的相关性。结果对照组FEV_1/FVC%、FEV_1占预计值%显著高于COPD患者组,差异有统计学意义(P<0.01);对照组血清HMGB1水平均值为1.75μg/L,COPD患者组为3.84μg/L,COPD患者血清HMGB1水平显著高于对照组,两组数值比较,差异有高度统计学意义(P<0.01);COPD患者血清HMGB1水平与FEV_1/FVC%和FEV_1占预计值%均呈负相关关系,差异有高度统计学意义(P<0.01)。结论 COPD患者血清HMGB1水平显著升高,且与肺功能呈负相关,提示血清HMGB1水平与慢性阻塞性肺疾病严重程度相关,对于疾病严重程度的判断具有一定的提示意义。
Objective To investigate the correlation between serum high mobility group protein B1(HMGB1) and chronic obstructive pulmonary disease(COPD) in patients with COPD. Methods A total of 73 patients with COPD who were treated in our hospital from January 2015 to May 2016 were selected as COPD group. Another 73 healthy subjects were selected as the control group.Forced expiratory volume in 1 second/forced vital capacity capacity(FEV_1/FVC%) and percentage of predicted forced expiratory volume in 1 Second(FEV_1) were used to evaluate the lung function of the two groups. The enzyme-linked immunosorbent assay(ELISA) was used to detect the serum HMGB1 levels of the two groups and the serum HMGB1 levels between the two groups were compared. The correlation between serum HMGB1 levels and pulmonary function was analyzed. Results The levels of FEV_1/FVC% and FEV_1% in the control group were significantly higher than those in the COPD group,and the difference was statistically significant(P<0.01). The serum HMGB1 level was 1.75 μg/L in the control group and 3.84 μg/L in the COPD group The serum HMGB1 level in patients with COPD was significantly higher than that in the control group,and the difference was statistically significant(P<0.01). There was a negative correlation between the levels of serum HMGB1 and FEV_1/FVC%, FEV_1% in the COPD patients with statistically significant(P<0.01). Conclusion The level of serum HMGB1 in patients with COPD is significantly elevated and is associated with the lung function, indicating that serum HMGB1 level is associated with the severity of chronic obstructive pulmonary disease and has a certain significance of determineing the severity of the disease.
Objective To investigate the correlation between serum high mobility group protein B1(HMGB1) and chronic obstructive pulmonary disease(COPD) in patients with COPD. Methods A total of 73 patients with COPD who were treated in our hospital from January 2015 to May 2016 were selected as COPD group. Another 73 healthy subjects were selected as the control group.Forced expiratory volume in 1 second/forced vital capacity capacity(FEV_1/FVC%) and percentage of predicted forced expiratory volume in 1 Second(FEV_1) were used to evaluate the lung function of the two groups. The enzyme-linked immunosorbent assay(ELISA) was used to detect the serum HMGB1 levels of the two groups and the serum HMGB1 levels between the two groups were compared. The correlation between serum HMGB1 levels and pulmonary function was analyzed. Results The levels of FEV_1/FVC% and FEV_1% in the control group were significantly higher than those in the COPD group,and the difference was statistically significant(P<0.01). The serum HMGB1 level was 1.75 μg/L in the control group and 3.84 μg/L in the COPD group The serum HMGB1 level in patients with COPD was significantly higher than that in the control group,and the difference was statistically significant(P<0.01). There was a negative correlation between the levels of serum HMGB1 and FEV_1/FVC%, FEV_1% in the COPD patients with statistically significant(P<0.01). Conclusion The level of serum HMGB1 in patients with COPD is significantly elevated and is associated with the lung function, indicating that serum HMGB1 level is associated with the severity of chronic obstructive pulmonary disease and has a certain significance of determineing the severity of the disease.
引文
[1]崔正森,李菡,姜宝珍,等.慢性阻塞性肺疾病、肺炎和肺癌患者血清HMGB1水平及临床意义[J].安徽医科大学学报,2014,49(6):812-815.
[2]侯嘉,马伟荣,刘洁,等.慢性阻塞性肺疾病患者肺组织和血清HMGB1的表达及与TNF-α和IL-1β的相关性[J].中国老年学杂志,2014,34(18):5064-5066.
[3]中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[J].全科医学临床与教育,2013,36(5):484-491.
[4]纪子梅,梅晓冬.慢性阻塞性肺疾病患者血清高迁移率族蛋白B1和纤维蛋白原的检测及意义[J].广东医学,2012,33(7):990-992.
[5]方晓聪,王向东,白春学.慢性阻塞性肺疾病在中国的诊治现状[J].国际呼吸杂志,2011,31(7):493-497.
[6]代灵灵,程哲,康燕,等.慢性阻塞性肺疾病患者诱导痰中细胞因子HMGB1的变化及临床意义[J].中国老年学杂志,2012,32(5):896-898.
[7]刘正会,李丽.炎症因子的变化在慢性阻塞性肺疾病病程发展中的应用探讨[J].临床肺科杂志,2013,18(9):1565-1567.
[8]Yanai H,Ban T,Taniguchi T.High-mobility group box family of proteins:Ligand and sensor for innate immunity[J].Trends in Immunology,2012,33(12):633-640.
[9]李新玲,吴振国,朱颀峰.慢性阻塞性肺疾病急性加重期血清白介素-6表达变化与肺炎衣原体感染的相关性[J].中华医院感染学杂志,2015,25(2):247-249.
[10]Gupta V,Banyard A,Mullan A,et al.Characterization of the inflammatory response to inhaled lipopolysaccharide in mild to moderate chronic obstructive pulmonary disease[J].British Journal of Clinical Pharmacology,2015,79(5):767-776.
[11]Venereau E,Schiraldi M,Uguccioni M,et al.HMGB1 and leukocyte migration during trauma and sterile inflammation[J].Molecular Immunology,2012,55(1):76-82.
[12]章俊强,梅晓冬.慢性阻塞性肺疾病患者支气管肺泡灌洗液中HMGB1的表达及意义[J].重庆医学,2016,45(8):1026-1028.
[13]Weitzenblum E,Chaouat A,Canuet M,et al.Pulmonary hypertension in chronic obstructive pulmonary disease and interstitial lung diseases[J].Semin Respir Crit Care Med,2009,30(4):458-470.
[14]Gabryel B,Bielecka A,Bernacki J,et al.Immunosuppressant cytoprotection correlates with HMGB1 suppression in primary astrocyte cultures exposed to combined oxygen-glucose deprivation[J].Pharmacological Reports Pr,2011,63(2):392-402.
[15]刘英,余海彬,刘小军,等.慢性阻塞性肺疾病大鼠肺组织高迁移率族蛋白B1水平的表达[J].中华实验外科杂志,2015,32(4):799-801.
[2]侯嘉,马伟荣,刘洁,等.慢性阻塞性肺疾病患者肺组织和血清HMGB1的表达及与TNF-α和IL-1β的相关性[J].中国老年学杂志,2014,34(18):5064-5066.
[3]中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[J].全科医学临床与教育,2013,36(5):484-491.
[4]纪子梅,梅晓冬.慢性阻塞性肺疾病患者血清高迁移率族蛋白B1和纤维蛋白原的检测及意义[J].广东医学,2012,33(7):990-992.
[5]方晓聪,王向东,白春学.慢性阻塞性肺疾病在中国的诊治现状[J].国际呼吸杂志,2011,31(7):493-497.
[6]代灵灵,程哲,康燕,等.慢性阻塞性肺疾病患者诱导痰中细胞因子HMGB1的变化及临床意义[J].中国老年学杂志,2012,32(5):896-898.
[7]刘正会,李丽.炎症因子的变化在慢性阻塞性肺疾病病程发展中的应用探讨[J].临床肺科杂志,2013,18(9):1565-1567.
[8]Yanai H,Ban T,Taniguchi T.High-mobility group box family of proteins:Ligand and sensor for innate immunity[J].Trends in Immunology,2012,33(12):633-640.
[9]李新玲,吴振国,朱颀峰.慢性阻塞性肺疾病急性加重期血清白介素-6表达变化与肺炎衣原体感染的相关性[J].中华医院感染学杂志,2015,25(2):247-249.
[10]Gupta V,Banyard A,Mullan A,et al.Characterization of the inflammatory response to inhaled lipopolysaccharide in mild to moderate chronic obstructive pulmonary disease[J].British Journal of Clinical Pharmacology,2015,79(5):767-776.
[11]Venereau E,Schiraldi M,Uguccioni M,et al.HMGB1 and leukocyte migration during trauma and sterile inflammation[J].Molecular Immunology,2012,55(1):76-82.
[12]章俊强,梅晓冬.慢性阻塞性肺疾病患者支气管肺泡灌洗液中HMGB1的表达及意义[J].重庆医学,2016,45(8):1026-1028.
[13]Weitzenblum E,Chaouat A,Canuet M,et al.Pulmonary hypertension in chronic obstructive pulmonary disease and interstitial lung diseases[J].Semin Respir Crit Care Med,2009,30(4):458-470.
[14]Gabryel B,Bielecka A,Bernacki J,et al.Immunosuppressant cytoprotection correlates with HMGB1 suppression in primary astrocyte cultures exposed to combined oxygen-glucose deprivation[J].Pharmacological Reports Pr,2011,63(2):392-402.
[15]刘英,余海彬,刘小军,等.慢性阻塞性肺疾病大鼠肺组织高迁移率族蛋白B1水平的表达[J].中华实验外科杂志,2015,32(4):799-801.